Feb 22 (Reuters) - Valeant Pharmaceuticals International Inc (N:VRX)
VRX.TO is expected to restate its earnings after an internal
review that likely concerns sales of its drugs to specialty
pharmacy Philidor Rx Services, CNBC reported, citing Dow Jones.
Valeant cut ties with Philidor in October after it was
revealed Philidor used aggressive tactics to try to increase
insurer reimbursement, mostly for dermatology drugs to help the
Canadian drugmaker inflate revenue.